Cassava Sciences Announces Presentation at the Jefferies Virtual Healthcare Conference and Provides Updates Regarding Phase 2...
June 03 2020 - 8:15AM
Cassava Sciences, Inc. (Nasdaq:SAVA), a clinical-stage
biotechnology company focused on Alzheimer’s disease, today
announced that management is scheduled to present at the Jefferies
Virtual Healthcare Conference today, June 3, 2020, at 3:00 pm EST.
Cassava Sciences also provided an update,
including a discussion regarding recently announced top-line
results of a Phase 2b randomized, placebo-controlled study of
PTI-125 in patients with Alzheimer’s disease. The Company believes
high variability in levels of biomarkers over 28 days in
placebo-treated patients, and other possible factors, may drive a
reassessment of overall results for its Phase 2b study. The update
is available in Cassava Sciences’ latest corporate presentation,
which can be accessed on the “Investors” page of the Company’s
website: https://www.CassavaSciences.com
“We think it’s worth reflecting on what can be
learned from our Phase 2b study by closely examining the clinical
data, methods used to generate the data and drug effects on
cognition,” said Remi Barbier, President & CEO. “These on-going
analyses may teach us how to move forward with our drug development
plans for PTI-125 in Alzheimer’s disease.”
Cassava Sciences’ latest corporate presentation
outlines a strategy to better understand the overall outcome of the
Phase 2b study of PTI-125. Key elements of this strategy include
plans to:
- Re-analyze cerebrospinal (CSF) samples from all study
participants;
- Analyze lymphocyte & plasma samples from all study
participants, which may provide direct evidence of target
engagement for PTI-125; and
- Evaluate effects of PTI-125 on cognition, which may provide
early evidence for stabilization, or even reversal, of cognitive
decline in patients with Alzheimer's.
Cassava Sciences expects to announce results of
these analyses in the second half of 2020.
About PTI-125Cassava Sciences’
lead therapeutic product candidate is for the treatment of
Alzheimer’s disease. PTI-125 is a proprietary, small molecule
(oral) drug that restores the normal shape and function of altered
filamin A (FLNA), a scaffolding protein, in the brain. Altered FLNA
in the brain disrupts the normal function of neurons, leading to
Alzheimer’s pathology, neurodegeneration and neuroinflammation. The
underlying science is published in peer-reviewed scientific
journals, including Journal of Neuroscience, Neurobiology of Aging,
Journal of Biological Chemistry and Journal of Prevention of
Alzheimer’s Disease. The Company is also developing an
investigational diagnostic, called SavaDx, to detect Alzheimer’s
disease with a simple blood test.
About Alzheimer's
Disease Alzheimer’s disease is a progressive brain
disorder that destroys memory and thinking skills. Currently, there
are no drug therapies to halt Alzheimer’s disease, much less
reverse its course. In the U.S. alone, approximately 5.8 million
people are currently living with Alzheimer’s disease, and
approximately 487,000 people age 65 or older developed Alzheimer’s
in 2019.1 The number of people living with Alzheimer’s disease is
expected to grow dramatically in the years ahead, resulting in a
growing social and economic burden.2
About Cassava Sciences,
Inc.The mission of Cassava Sciences, Inc. is to detect and
treat neurodegenerative diseases, such as Alzheimer’s disease. Over
the past 10 years, Cassava Sciences has combined state-of-the-art
technology with new insights in neurobiology to develop novel
solutions for Alzheimer’s disease. Cassava Sciences owns worldwide
development and commercial rights to its research programs in
Alzheimer’s disease, and related technologies, without royalty
obligations to any third-party.
For more information, please visit:
https://www.CassavaSciences.com
For Media Inquiries
Contact:Kirsten Thomas, SVP The Ruth
Groupkthomas@TheRuthGroup.com (508) 280-6592
Cautionary Note Regarding
Forward-Looking Statements: This press release contains
“forward-looking statements” for purposes of the Private Securities
Litigation Reform Act of 1995 (the Act). Cassava Sciences,
Inc. claims the protection of the Safe Harbor for forward-looking
statements contained in the Act. All statements other than
statements of historical fact contained in this press release
including, but not limited to statements regarding the status of
clinical studies with PTI-125; the interpretation of results of
clinical studies, potential health benefits, if any, of changes in
levels of biomarkers; variability in levels of biomarkers of
disease; plans to have CSF samples from all Phase 2b study
participants re-analyzed; the potential for a reassessment of Phase
2b study results; the planned analysis of lymphocyte, plasma and
cognition data; verbal commentaries made by Cassava Sciences’
employees; and potential benefits, if any, of the Company’s product
candidates for Alzheimer’s disease, are all forward-looking
statements. Such statements are based largely on the Company’s
current expectations and projections about future events. Such
statements speak only as of the date of this press release and are
subject to a number of risks, uncertainties and assumptions,
including, but not limited to, those risks relating to the ability
to conduct or complete clinical studies on expected timelines, to
demonstrate the specificity, safety, efficacy or potential health
benefits of our product candidates, the severity and duration of
health care precautions given the COVID-19 pandemic, any
unanticipated impacts of the pandemic on our business operations,
and including those described in the section entitled “Risk
Factors” in Cassava Sciences’ Annual Report on Form 10-K for the
year ended December 31, 2019 and future reports to be filed with
the SEC. In light of these risks, uncertainties and assumptions,
the forward-looking statements and events discussed in this press
release are inherently uncertain and may not occur, and actual
results could differ materially and adversely from those
anticipated or implied in the forward-looking statements.
Accordingly, you should not rely upon forward-looking statements as
predictions of future events. Except as required by law, the
Company disclaims any intention or responsibility for updating or
revising any forward-looking statements contained in this press
release. For further information regarding these and other risks
related to our business, investors should consult our filings with
the SEC, which are available on the SEC's website at
www.sec.gov.
1, 2 Source: Alzheimer’s Association. 2019 Alzheimer’s Disease
Facts and Figures. Available online at:
https://www.alz.org/media/documents/alzheimers-facts-and-figures-2019-r.pdf
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Apr 2023 to Apr 2024